Article

Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 42, n° 5P1
pages 829-830 (mai 2000)
Doi : 10.1067/mjd.2000.105948
Treatment with anti-tumor necrosis factor ⍺ (TNF-⍺) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions
 

Charles J. Oh, MD, Kiron M. Das, MD, PhD, Alice B. Gottlieb, MD, PhD
Divisions of Clinical Pharmacology and Gastroenterology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School. New Brunswick, New Jersey 

Abstract

We treated a 57-year-old woman for refractory inflammatory bowel disease with a humanized anti–tumor necrosis factor ⍺ monoclonal antibody (Infliximab). The patient also had a 15-year history of Crohn’s disease and a 20-year history of moderate to severe psoriasis. She received a single infusion of Infliximab (5 mg/kg). Two weeks after the infusion her psoriasis had dramatically improved in appearance. To our knowledge, our case is the first reported instance of successful anti–tumor necrosis factor ⍺ therapy in psoriasis. (J Am Acad Dermatol 2000;42:829-30.)

The full text of this article is available in PDF format.

 Reprint requests: Alice B. Gottlieb, MD, PhD, Clinical Research Center, One Robert Wood Johnson Place, Box 19, New Brunswick, NJ 08903. E-mail: gottliab@umdnj.edu.


Top of the page

© 2000  American Academy of Dermatology, Inc. Published by Elsevier Masson SAS@@#104157@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline
You can move this window by clicking on the headline
@@#110903@@